The neglected association between schizophrenia and bone fragility: a systematic review and meta-analyses.
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
30 May 2024
30 May 2024
Historique:
received:
09
02
2023
accepted:
18
03
2024
revised:
13
03
2024
medline:
31
5
2024
pubmed:
31
5
2024
entrez:
30
5
2024
Statut:
epublish
Résumé
Schizophrenia is associated with increased risk of medical comorbidity, possibly including osteoporosis, which is a public health concern due to its significant social and health consequences. In this systematic review and meta-analysis, we aimed to determine whether schizophrenia is associated with bone fragility. The protocol for this review has been registered with PROSPERO (CRD42020171959). The research question and inclusion/exclusion criteria were developed and presented according to the PECO (Population, Exposure, Comparison, Outcome) framework. Schizophrenia was identified from medical records, DSM-IV/5 or the ICD. The outcomes for this review were bone fragility [i.e., bone mineral density (BMD), fracture, bone turnover markers, bone quality]. A search strategy was developed and implemented for the electronic databases. A narrative synthesis was undertaken for all included studies; the results from eligible studies reporting on BMD and fracture were pooled using a random effects model to complete a meta-analysis. The conduct of the review and reporting of results adhered to PRISMA guidelines. Our search yielded 3103 studies, of which 29 met the predetermined eligibility criteria. Thirty-seven reports from 29 studies constituted 17 studies investigating BMD, eight investigating fracture, three investigating bone quality and nine investigating bone turnover markers. The meta-analyses revealed that people with schizophrenia had lower BMD at the lumbar spine [standardised mean difference (SMD) -0.74, 95% CI -1.27, -0.20; Z = -2.71, p = 0.01] and at the femoral neck (SMD -0.78, 95% CI -1.03, -0.53; Z = -6.18, p ≤ 0.001). Also observed was a higher risk of fracture (OR 1.43, 95% CI 1.27, 1.61; Z = 5.88, p ≤ 0.001). Following adjustment for publication bias, the association between schizophrenia and femoral neck BMD (SMD -0.63, 95% CI -0.97, -0.29) and fracture (OR 1.32, 95% CI 1.28, 1.35) remained. Significantly increased risk of bone fragility was observed in people with schizophrenia. This association was independent of sex, participant number, methodological quality and year of publication.
Identifiants
pubmed: 38816361
doi: 10.1038/s41398-024-02884-1
pii: 10.1038/s41398-024-02884-1
doi:
Types de publication
Journal Article
Systematic Review
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
225Informations de copyright
© 2024. The Author(s).
Références
Reginster J-Y, Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006;38:4–9.
doi: 10.1016/j.bone.2005.11.024
Nshimyumukiza L, Durand A, Gagnon M, Douville X, Duplantie J, Reinharz D, et al. An economic evaluation: Simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures. J Bone Miner Res. 2013;28:383–94.
pubmed: 22991210
doi: 10.1002/jbmr.1758
WHO. assessment of fracture risk and its application to screening for postmenopausal osteoporosis. 1994.
Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359:1929–36.
pubmed: 12057569
doi: 10.1016/S0140-6736(02)08761-5
Pasco JA, Lane SE, Brennan-Olsen SL, Holloway KL, Timney EN, Bucki-Smith G, et al. The epidemiology of incident fracture from cradle to senescence. Calcified Tissue Int. 2015;97:568–76.
doi: 10.1007/s00223-015-0053-y
Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone. 1995;17:505–11.
doi: 10.1016/8756-3282(95)00258-4
Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Anastassiades T, Pickard L, et al. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. Cmaj. 2009;181:265–71.
pubmed: 19654194
pmcid: 2734204
doi: 10.1503/cmaj.081720
Pasco JA, Sanders KM, Hoekstra FM, Henry MJ, Nicholson GC, Kotowicz MA. The human cost of fracture. Osteoporos Int. 2005;16:2046–52.
pubmed: 16228106
doi: 10.1007/s00198-005-1997-y
Pasco JA, Mohebbi M, Holloway KL, Brennan-Olsen SL, Hyde NK, Kotowicz MA. Musculoskeletal decline and mortality: prospective data from the Geelong Osteoporosis Study. J Cachexia Sarcopenia Muscle. 2017;8:482–9.
pubmed: 28025860
doi: 10.1002/jcsm.12177
Garnero P, Delmas PD. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact. 2004;4:50–63.
pubmed: 15615078
Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int. 2006;17:1404–9.
pubmed: 16699736
doi: 10.1007/s00198-006-0135-9
Otmar RKM, Brennan SL, Bucki-Smith G, Korn S, Pasco JA. Personal and psychosocial impacts of clinical fracture in men. J Men’s Health. 2013;10:22–7.
Global, regional, and national burden of bone fractures in 204 countries and territories. 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2021;2:e580–e92.
doi: 10.1016/S2666-7568(21)00172-0
Fu Y, Li C, Luo W, Chen Z, Liu Z, Ding Y. Fragility fracture discriminative ability of radius quantitative ultrasound: a systematic review and meta-analysis. Osteoporos Int. 2021;32:23–38.
pubmed: 32728897
doi: 10.1007/s00198-020-05559-x
Engelke K, Libanati C, Fuerst T, Zysset P, Genant HK. Advanced CT based in vivo methods for the assessment of bone density, structure, and strength. Curr Osteoporos Rep. 2013;11:246–55.
pubmed: 23712690
doi: 10.1007/s11914-013-0147-2
Glendenning P, Chubb SAP, Vasikaran S. Clinical utility of bone turnover markers in the management of common metabolic bone diseases in adults. Clin Chim Acta. 2018;481:161–70.
pubmed: 29544749
doi: 10.1016/j.cca.2018.03.009
Guo P, Wang S, Zhu Y, Shen X, Jin X, Qian M, et al. Prevalence of osteopenia and osteoporosis and factors associated with decreased bone mineral density in elderly inpatients with psychiatric disorders in Huzhou, China. Shanghai Arch Psychiatry. 2012;24:262–69.
pubmed: 25328349
pmcid: 4198874
Janssen EM, McGinty EE, Azrin ST, Juliano-Bult D, Daumit GL. Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness. Gen Hosp Psychiatry. 2015;37:199–222.
pubmed: 25881768
pmcid: 4663043
doi: 10.1016/j.genhosppsych.2015.03.004
Kishimoto T, De Hert M, Carlson HE, Manu P, Correll CU. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry. 2012;25:415–29.
pubmed: 22744405
pmcid: 3566242
doi: 10.1097/YCO.0b013e328355e1ac
Halbreich U. Osteoporosis, schizophrenia and antipsychotics: The need for a comprehensive multifactorial evaluation. CNS Drugs. 2007;21:641–57.
pubmed: 17630817
doi: 10.2165/00023210-200721080-00003
O’Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol. 2008;22:70–5.
pubmed: 18477623
doi: 10.1177/0269881107088439
Sadock BJ, Sadock VA, Ruiz MT Kaplan & Sadock’s Concise Textbook of Clinical Psychiatry: Wolters Kluwer Health; 2016.
Halbreich U, Palter S. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull. 1996;22:447–54.
pubmed: 8873295
doi: 10.1093/schbul/22.3.447
Lee TY, Chung MY, Chung HK, Choi JH, Kim TY, So HS. Bone density in chronic schizophrenia with long-term antipsychotic treatment: Preliminary study. Psychiatry Investig. 2010;7:278–84.
pubmed: 21253412
pmcid: 3022315
doi: 10.4306/pi.2010.7.4.278
Wu H, Deng L, Zhao L, Zhao J, Li L, Chen J. Osteoporosis associated with antipsychotic treatment in Schizophrenia. Int J Endocrinol. 2013;2013:167138.
pubmed: 23690768
pmcid: 3652172
doi: 10.1155/2013/167138
Stubbs B, Gaughran F, Mitchell AJ, De Hert M, Farmer R, Soundy A, et al. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis. Gen Hosp Psychiatry. 2015;37:126–33.
pubmed: 25666994
doi: 10.1016/j.genhosppsych.2015.01.004
Tsai KY, Lee CC, Chou YM, Shen SP, Su CY, Wu HC, et al. The risks of major osteoporotic fractures in patients with schizophrenia: a population-based 10-year follow-up study. Schizophr Res. 2014;159:322–8.
pubmed: 25445622
doi: 10.1016/j.schres.2014.09.032
Vancampfort D, Knapen J, Probst M, Scheewe T, Remans S, De Hert M. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand. 2012;125:352–62.
pubmed: 22176559
doi: 10.1111/j.1600-0447.2011.01814.x
Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res. 2013;47:197–207.
pubmed: 23153955
doi: 10.1016/j.jpsychires.2012.10.005
de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76:135–57.
pubmed: 15949648
doi: 10.1016/j.schres.2005.02.010
Crews MP, Howes OD. Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications. Hum Psychopharmacol. 2012;27:15–23.
pubmed: 22228316
pmcid: 3731625
doi: 10.1002/hup.1265
Stubbs B. Antipsychotic-induced hyperprolactinaemia in patients with schizophrenia: considerations in relation to bone mineral density. J Psychiatr Ment Health Nurs. 2009;16:838–42.
pubmed: 19824978
doi: 10.1111/j.1365-2850.2009.01472.x
Kinon BJ, Liu-Seifert H, Stauffer VL, Jacob J. Bone loss associated with hyperprolactinemia in patients with schizophrenia. Clin Schizophrenia Related Psychoses. 2013;7:115–23.
doi: 10.3371/CSRP.KISE.020113
Partti K, Heliovaara M, Impivaara O, Perala J, Saarni SI, Lonnqvist J, et al. Skeletal status in psychotic disorders: a population-based study. Psychosom Med. 2010;72:933–40.
pubmed: 20841556
doi: 10.1097/PSY.0b013e3181f7abd3
Holt RIG. Osteoporosis in people with severe mental illness: a forgotten condition. Maturitas. 2010;67:1–2.
pubmed: 20591586
doi: 10.1016/j.maturitas.2010.06.004
Menendez ME, Neuhaus V, Bot AGJ, Vrahas MS, Ring D. Do psychiatric comorbidities influence inpatient death, adverse events, and discharge after lower extremity fractures? Clin Orthopaedics Related Res®. 2013;471:3336–48.
doi: 10.1007/s11999-013-3138-9
Zachwieja E, Butler AJ, Grau LC, Summers S, Massel D, Orozco F, et al. The association of mental health disease with perioperative outcomes following femoral neck fractures. J Clin Orthop Trauma. 2019;10:S77–S83.
pubmed: 31695264
pmcid: 6823790
doi: 10.1016/j.jcot.2019.01.002
Javaid MK, Holt RIG. Understanding osteoporosis. J Psychopharmacol. 2008;22:38–45.
pubmed: 18477619
doi: 10.1177/0269881107087955
Stubbs B, De Hert M, Sepehry AA, Correll CU, Mitchell AJ, Soundy A, et al. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand. 2014;130:470–86.
pubmed: 25041606
doi: 10.1111/acps.12313
Tseng PT, Chen YW, Yeh PY, Tu KY, Cheng YS, Wu CK. Bone mineral density in schizophrenia: an update of current meta-analysis and literature review under guideline of PRISMA. Medicine (Baltimore). 2015;94:e1967.
pubmed: 26632691
doi: 10.1097/MD.0000000000001967
Gomez L, Stubbs B, Shirazi A, Vancampfort D, Gaughran F, Lally J. Lower bone mineral density at the hip and lumbar spine in people with psychosis versus controls: a comprehensive review and skeletal site-specific meta-analysis. Curr Osteoporosis Rep. 2016;14:249–59.
doi: 10.1007/s11914-016-0325-0
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
pubmed: 33782057
pmcid: 8005924
doi: 10.1136/bmj.n71
Azimi Manavi B, Stuart AL, Pasco JA, Hodge JM, Corney KB, Berk M, et al. Study protocol for the systematic review and meta- analyses of the association between schizophrenia and bone fragility. BMJ Open. 2020;10:e041859.
pubmed: 33310808
pmcid: 7735127
doi: 10.1136/bmjopen-2020-041859
Diagnostic and statistical manual of mental disorders: DSM-5. Fifth edition. ed: American Psychiatric Association; 2013.
(WHO) WHO. International Classification of Diseases for Mortality and Morbidity Statistics (Eleventh Revision): World Health Organization; 2018 [Available from: https://icd.who.int/en/ .
Bonjour JP, Ammann P, Rizzoli R. Importance of preclinical studies in the development of drugs for treatment of osteoporosis: a review related to the 1998 WHO guidelines. Osteoporos Int. 1999;9:379–93.
pubmed: 10550456
doi: 10.1007/s001980050161
Hlaing TT, Compston JE. Biochemical markers of bone turnover - uses and limitations. Ann Clin Biochem. 2014;51:189–202.
pubmed: 24399365
doi: 10.1177/0004563213515190
Covidence Systematic Review Software, Veritas Health Innovation: Melbourne, Australia; [Available from: www.covidence.org .
Altındağ Ö, Altındağ A, Vırıt O, Savaş HA, Yılmaz M, Bozgeyik Ö, et al. Bone mineral density in schizophrenia patients on antipsychotics. Bull. Clin. Psychopharmacol. 2009;19:402–6.
Wyszogrodzka-Kucharska A, Rabe-Jabłońska J. Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics. Psychiatr Pol. 2005;39:1173–84.
pubmed: 16526183
NHLBI. Study Quality Assessment Tools 2013 [updated July, 2021. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools .
Guidance for effect size [Available from: https://ican.org.uk/media/3542/guidance_for_effect_size_calculation.pdf .
Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254–9.
pubmed: 8634613
pmcid: 2351094
doi: 10.1136/bmj.312.7041.1254
Leslie WD, Kovacs CS, Olszynski WP, Towheed T, Kaiser SM, Prior JC, et al. Spine-hip T-score difference predicts major osteoporotic fracture risk independent of FRAX(®): a population-based report from CAMOS. J Clin Densitom. 2011;14:286–93.
pubmed: 21723768
pmcid: 5096935
doi: 10.1016/j.jocd.2011.04.011
Higgins JT, J. Cochrane handbook for systematic reviews of interventions version 6.3: The Cochrane collaboration; 2022 [Available from: https://training.cochrane.org/handbook/current/chapter-06#section-6-5-2-10 .
Webb Pa, Bain C, Page A Essential epidemiology: an introduction for students and health professionals. Fourth edition. ed: Cambridge University Press; 2020.
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
pubmed: 9310563
pmcid: 2127453
doi: 10.1136/bmj.315.7109.629
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.
pubmed: 7786990
doi: 10.2307/2533446
Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.
pubmed: 10877304
doi: 10.1111/j.0006-341X.2000.00455.x
Bergemann N, Parzer P, Mundt C, Auler B. High bone turnover but normal bone mineral density in women suffering from schizophrenia. Psychol Med. 2008;38:1195–201.
pubmed: 18366816
doi: 10.1017/S003329170800319X
Bolton JM, Targownik LE, Leung S, Sareen J, Leslie WD. Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psychopharmacol. 2011;31:56–60.
pubmed: 21192144
doi: 10.1097/JCP.0b013e3182075587
Chiang TI, Lane HY, Lin CH. D2 dopamine receptor gene (DRD2) Taq1A (rs1800497) affects bone density. Sci Rep. 2020;10:13236.
pubmed: 32764574
pmcid: 7414035
doi: 10.1038/s41598-020-70262-0
Cui J, Liu H, Shao J, Xu DM, Wang Y, Fei Z, et al. Prevalence, risk factors and clinical characteristics of osteoporosis in Chinese inpatients with schizophrenia. Schizophr Res. 2018;195:488–94.
pubmed: 29056492
doi: 10.1016/j.schres.2017.10.027
Doknic M, Maric NP, Britvic D, Pekic S, Damjanovic A, Miljic D, et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology. 2011;94:246–54.
pubmed: 21986470
doi: 10.1159/000329391
Du X, Ye F, Li J, Zhao Y, Xiao W, Tang X, et al. Altered levels of BMD, PRL, BAP and TRACP-5b in male chronic patients with schizophrenia. Sci Rep. 2020;10:13598.
pubmed: 32788631
pmcid: 7423890
doi: 10.1038/s41598-020-70668-w
Jung DU, Conley RR, Kelly DL, Kim DW, Yoon SH, Jang JH, et al. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry. 2006;67:1391–6.
pubmed: 17017825
doi: 10.4088/JCP.v67n0909
Jung D-U, Kelly DL, Oh M-K, Kong B-G, Kang J-W, Lee S-J, et al. Bone mineral density and osteoporosis risk in older patients with schizophrenia. J Clin Psychopharmacol. 2011;31:406–10.
pubmed: 21694624
doi: 10.1097/JCP.0b013e318221b123
Keely EJ, Reiss JP, Drinkwater DT, Faiman C. Bone mineral density, sex hormones, and long-term use of neuroleptic agents in men. Endocr Pract. 1997;3:209–13.
pubmed: 15251791
doi: 10.4158/3.4.209
Kishimoto T, Watanabe K, Shimada N, Makita K, Yagi G, Kashima H. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo- pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008;69:385–91.
pubmed: 18278991
doi: 10.4088/JCP.v69n0307
Koçer E, Yazıcı S, Canan F. Comparison of bone mineral density levels in young-adult patients with schizophrenia and healthy controls / Genç-erişkin şizofreni hastalarında kemik mineral yoğunluğu düzeyinin sağlıklı kontrollerle karşılaştırılması. Dusunen Adam: J Psychiatry Neurol Sci. 2011;24:314–20.
doi: 10.5350/DAJPN2011240407
Liang M, Zhang B, Deng L, Xu R, Wu H, Chen J. Effects of olanzapine on bone mineral density, glucose, and lipid metabolism in Schizophrenia patients. Int J Endocrinol. 2019;1312804:1–9.
Lin C-H, Lin C-Y, Wang H-S, Lane H-Y. Long-term use of clozapine is protective for bone density in patients with Schizophrenia. Sci Rep. 2019;9:3895. -
pubmed: 30846868
pmcid: 6405997
doi: 10.1038/s41598-019-40691-7
Wang M, Hou R, Jian J, Mi G, Qiu H, Cao B, et al. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. Human Psychopharmacol: Clin Exp. 2014;29:183–9.
doi: 10.1002/hup.2387
Chen Y, Zhang Y, Fan K, Xu W, Teng C, Wang S, et al. Association between gonadal hormones and osteoporosis in schizophrenia patients undergoing risperidone monotherapy: a cross-sectional study. PeerJ. 2021;9:e11332.
pubmed: 33987015
pmcid: 8086585
doi: 10.7717/peerj.11332
Collinge CA, Lebus G, Gardner MJ, Gehrig L. A comparison of quantitative ultrasound of the calcaneus with dual-energy x-ray absorptiometry in hospitalized orthopaedic trauma patients. J Orthop Trauma. 2010;24:176–80.
pubmed: 20182254
doi: 10.1097/BOT.0b013e3181b8b036
Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry. 2007;190:129–34.
Bolton JM, Metge C, Lix L, Prior H, Sareen J, Leslie WD. Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol. 2008;28:384–91.
pubmed: 18626264
doi: 10.1097/JCP.0b013e31817d5943
Bolton JM, Morin SN, Majumdar SR. Association of mental disorders and related medication use with risk for major osteoporotic fractures. JAMA Psychiatry. 2017;74:641–48.
pubmed: 28423154
pmcid: 5539842
doi: 10.1001/jamapsychiatry.2017.0449
Bishop JR, Alexander B, Lund BC, Klepser TB. Osteoporosis screening and treatment in women with schizophrenia: a controlled study. Pharmacotherapy. 2004;24:515–21.
pubmed: 15098807
doi: 10.1592/phco.24.5.515.33346
Sorensen HJ, Jensen SO, Nielsen J. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis. Eur Neuropsychopharmacol. 2013;23:872–8.
pubmed: 23642346
doi: 10.1016/j.euroneuro.2013.04.002
Chu Y-W, Chen W-P, Yang AC, Tsai S-J, Hu L-Y, Lee S-C, et al. Hip, vertebral, and wrist fracture risks and schizophrenia: a nationwide longitudinal study. BMC Psychiatry. 2022;22:77.
pubmed: 35105317
pmcid: 8805461
doi: 10.1186/s12888-022-03723-7
Rey-Sanchez P, Lavado-Garcia JM, Canal-Macias ML, Gomez-Zubeldia MA, Roncero-Martin R, Pedrera-Zamorano JD. Ultrasound bone mass in schizophrenic patients on antipsychotic therapy. Hum Psychopharmacol. 2009;24:49–54.
pubmed: 19016257
doi: 10.1002/hup.984
Renn JH, Yang NP, Chueh CM, Lin CY, Lan TH, Chou P. Bone mass in schizophrenia and normal populations across different decades of life. BMC Musculoskelet Disord. 2009;10:1.
pubmed: 19118498
pmcid: 2642755
doi: 10.1186/1471-2474-10-1
Okita K, Kanahara N, Nishimura M, Yoshida T, Yasui-Furukori N, Niitsu T, et al. Second-generation antipsychotics and bone turnover in schizophrenia. Schizophr Res. 2014;157:137–41.
pubmed: 24888527
doi: 10.1016/j.schres.2014.05.009
Zhang B, Deng L, Wu H, Lu X, Peng L, Wu R, et al. Relationship between long-term use of a typical antipsychotic medication by Chinese schizophrenia patients and the bone turnover markers serum osteocalcin and beta-CrossLaps. Schizophr Res. 2016;176:259–63.
pubmed: 27377977
doi: 10.1016/j.schres.2016.06.034
Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in Schizophrenia. Ann Rev Clin Psychol. 2014;10:425–48.
doi: 10.1146/annurev-clinpsy-032813-153657
Bailey DA, Martin AD, McKay HA, Whiting S, Mirwald R. Calcium accretion in girls and boys during puberty: a longitudinal analysis. J Bone Miner Res. 2000;15:2245–50.
pubmed: 11092406
doi: 10.1359/jbmr.2000.15.11.2245
Lally J, Ajnakina O, Singh N, Gardner-Sood P, Stubbs B, Stringer D, et al. Vitamin D and clinical symptoms in First Episode Psychosis (FEP): a prospective cohort study. Schizophr Res. 2019;204:381–8.
pubmed: 30154029
doi: 10.1016/j.schres.2018.08.011
Pasco JA, Henry MJ, Kotowicz MA, Sanders KM, Seeman E, Pasco JR, et al. Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study. J Bone Miner Res. 2004;19:752–8.
pubmed: 15068498
doi: 10.1359/jbmr.040125
Nakamichi M, Wakabayashi H, Nishioka S, Momosaki R. Influence of antipsychotics on functional prognosis after geriatric hip fracture. J Nutr Health Aging. 2019;23:381–5.
pubmed: 30932138
doi: 10.1007/s12603-019-1173-2
Oderda LH, Young JR, Asche CV, Pepper GA. Psychotropic-related hip fractures: meta-analysis of first-generation and second-generation antidepressant and antipsychotic drugs. Ann Pharmacother. 2012;46:917–28.
pubmed: 22811347
doi: 10.1345/aph.1Q589
Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17:341–56.
pubmed: 30192094
pmcid: 6127750
doi: 10.1002/wps.20567
Rosso IM, Bearden CE, Hollister JM, Gasperoni TL, Sanchez LE, Hadley T, et al. Childhood neuromotor dysfunction in schizophrenia patients and their unaffected siblings: a prospective cohort study. Schizophr Bull. 2000;26:367–78.
pubmed: 10885637
doi: 10.1093/oxfordjournals.schbul.a033459
Houseknecht KL, Bouchard CC, Black CA. Elucidating the mechanism(s) underlying antipsychotic and antidepressant-mediated fractures. J Ment Health Clin Psychol. 2017;1:9–13.
pubmed: 31008454
pmcid: 6469345
doi: 10.29245/2578-2959/2018/1.1106